We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate, CT1812, is an o... Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate, CT1812, is an orally delivered, small molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.08 | 4.27807486631 | 1.87 | 2.1 | 1.79 | 118859 | 1.92878836 | CS |
4 | 0.05 | 2.63157894737 | 1.9 | 2.1599 | 1.79 | 135440 | 1.96525725 | CS |
12 | -0.35 | -15.2173913043 | 2.3 | 2.4603 | 1.75 | 210306 | 1.96254235 | CS |
26 | 0.89 | 83.9622641509 | 1.06 | 2.79 | 0.9001 | 194300 | 1.87197882 | CS |
52 | 0.16 | 8.93854748603 | 1.79 | 3.49 | 0.9001 | 156878 | 1.90566119 | CS |
156 | -10.2 | -83.950617284 | 12.15 | 13.8 | 0.9001 | 165806 | 3.08690045 | CS |
260 | -10.2 | -83.950617284 | 12.15 | 13.8 | 0.9001 | 165806 | 3.08690045 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions